U.S. markets open in 2 hours 55 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
152.68-6.31 (-3.97%)
At close: 4:00PM EDT

151.52 -1.16 (-0.76%)
Pre-Market: 6:22AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close158.99
Bid0.00 x 1200
Ask0.00 x 1100
Day's Range151.15 - 158.91
52 Week Range46.13 - 189.26
Avg. Volume10,202,363
Market Cap61.305B
Beta (5Y Monthly)1.46
PE Ratio (TTM)102.33
EPS (TTM)1.49
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Editor's Pick
    Yahoo Finance Video

    CDC panel endorses Pfizer’s Covid vaccine for use in adolescents

    Dr. Jonathan Javitt, CEO of NeuroRX & adjunct professor at Johns Hopkins School of Medicine, joined Yahoo Finance to discuss the latest on covid-19.

  • Reuters

    INSIGHT-Top scientists question the need for COVID-19 booster shots

    In interviews with Reuters, more than a dozen influential infectious disease and vaccine development experts said there is growing evidence that a first round of global vaccinations may offer enduring protection against the coronavirus and its most worrisome variants discovered to date. "We don't see the data yet that would inform a decision about whether or not booster doses are needed," said Kate O'Brien, director of the Department of Immunization, Vaccines and Biologicals at the World Health Organization (WHO). O'Brien said the WHO is forming a panel of experts to assess all variant and vaccine efficacy data and recommend changes to vaccination programs as needed.

  • Moderna Signs 25M COVID-19 Vaccine Doses Supply Deal With Australia; Shares Dip 4%

    Moderna Signs 25M COVID-19 Vaccine Doses Supply Deal With Australia; Shares Dip 4%

    Moderna, Inc. (MRNA) has won a new order for the supply of 25 million doses of its COVID-19 vaccine to Australia. Shares plunged almost 4% on May 12 to close at $152.68. The biotech company said that the new order includes 10 million doses of mRNA-1273 which will be delivered this year. The remaining 15 million doses which consist of Moderna’s updated variant booster vaccine candidate will be delivered by 2022. Moderna is likely to seek necessary approvals from the regulators as well as from the Therapeutic Goods Administration (TGA) of Australia, prior to the distribution of COVID-19 Vaccine doses, the company said. Earlier this year, Moderna announced its intent to open a commercial subsidiary in Australia in 2021 in a bid to expand its commercial network. Moderna CEO Stephane Bancel said, “We appreciate the partnership and support from the government of Australia with this first supply agreement for doses of the Moderna COVID-19 vaccine and our variant booster candidates”. Bancel added, “As we seek to protect people around the world with our COVID-19 vaccine and potentially our variant booster candidates, we look forward to continuing discussions with Australia about establishing potential local manufacturing opportunities.” (See Moderna stock analysis on TipRanks) Recently, the company reported better-than-expected Q1 earnings and the first profitable quarter in its history. The company recorded earnings of $2.84 per share, compared to a loss of $0.35 in the prior-year quarter, and surpassed the Street’s estimates of $2.39. However, total revenue of $1.94 billion missed analysts’ expectations of $2.04 billion. Last week, J.P. Morgan analyst Cory Kasimov increased the stock’s price target to $127 (16.8% downside potential) from $121 and reiterated a Hold rating. Kasimov said, “We should see a material step up in future quarters as vaccine is delivered on a more global basis (counterintuitive to the typical biopharma biz model). We are optimistic on MRNA’s long term prospects and do believe that mRNA-1273 will generate an enormous amount of capital for the company near term.” “The possibility of a potential supply glut of COVID-19 vaccines and the uncertain duration of pandemic leaves us relatively cautious on the substantial amount of value that the market is already ascribing to this true game changing product,” the analyst added. The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 6 Buys, 4 Holds, and 2 Sells. The average analyst price target of $174.18 implies 14.1% upside potential to current levels. Shares have gained almost 71% so far over the past six months. Furthermore, TipRanks data shows that financial blogger opinions are 83% Bullish on Moderna, compared to a sector average of 70%. Related News: Cryptocurrencies Are Gaining Momentum With New Launches Lucira’s COVID-19 Self-Test Now Available On Amazon; Shares Rise 38% Electronic Arts Delivers Impressive FY21 Results, Announces Dividend More recent articles from Smarter Analyst: Upstart Holdings Posts 340% Earnings Growth In Q1: Shares Jump 3% Dye & Durham Posts 300% Revenue Growth In 3Q: Shares Jump 6% Boyd Group Services 1Q Profit Falls 55%; Shares Drop 6% Crescent Point Energy Swings To A 1Q Profit On Higher Oil Prices; Shares Pop 4%